VolitionRx Discusses Promising Clinical Trials Results for its Novel COVID-19 Triage Test

(12:36)

VolitionRx Discusses $28 Million Licensing Deal with Heska and Focus for 2022

(4:53)

VolitionRx Breaks Down Supply Agreement of Nu.Q® Vet Cancer Tests with IDEXX Laboratories

(11:33)

VolitionRx – Commercializing the Nu.Q Vet Cancer Test: Webinar

(36:37)

Volition’s Nu.Q(TM) Vet Assay Detects Two Common Canine Cancers

(2:26)

VolitionRx Provides Update on Animal Health Blood Test Program, Licensing Deals and Focus for 2021

(10:16)

Executive interview - VolitionRX discusses Q319 results and provides a business update

(7:56)

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

(3:23)

VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

(3:42)

Management of Polycythemia Vera with Dr. Aaron Gerds

(56:45)

You Need To Pay Attention To Volition Stock NYSE: VNRX

(1:48)

FLORIAN HOMM Vortrag auf der World of Trading

(42:50)

Bias Diagnosis – Dr Ronx on how gender bias can affect the way pain is treated

(4:35)

Bioverse Episode 10 - The Winners, Losers, and Dark Horses of ASCO24 \u0026 BIO2024 tidbits

(1:41:35)

Revolutionizing The Diagnosis of Life-Altering Diseases - VolitionRx Limited. at GCFF Nov 16, 2022

(18:51)

Controversy at the Tanis Site

(14:18)

Volition Webinar: Unraveling the web of NETs in sepsis

(41:38)

Volition webinar: Nu.Q NETs data insights

(57:12)

Volition signs exclusive license and supply agreement with Heska Corporation.

(5:46)

VolitionRx on Commercial Launch of Cancer Screen Test for Canines and Veterinary Market Opportunity

(10:3)

VolitionRx - executive interview

(9:12)

Cancer Diagnosis by Blood Tests: VolitionRx Limited (NYSE AMERICAN: VNRX) Presents at GCFF Jun10

(19:43)

VolitionRx chief: US patent crucial for long-term value

(9:2)

VolitionRx (VNRX) - Cameron Reynolds President \u0026 CEO

(25:12)

Executive Interview - VolitionRx

(8:11)

VolitionRx Limited Announces Interim Results from a 680-Subject Clinical Trial in Colorectal Cancer

(5:26)

VolitionRx acquires epigenetic reagent company Octamer GmbH

(3:27)

VolitionRx - executive interview

(8:2)